AbbVie Submits SNDA To FDA For Venclexta-Acalabrutinib Combo In Frontline CLL

AbbVie has submitted a supplemental New Drug Software program (sNDA) to the FDA for the approval of Venclexta (venetoclax) along with acalabrutinib in beforehand untreated victims with energy lymphocytic leukemia (CLL).¹

AMPLIFY analysis helps time-limited oral combination

The submission is supported by optimistic data from the Part III AMPLIFY medical trial (NCT03836261). Inside the analysis, the combo routine of Venclexta and acalabrutinib improved progression-free survival (PFS) as compared with commonplace chemoimmunotherapy in beforehand untreated victims with CLL.

In a press launch, Svetlana Kobina, vice chairman, worldwide medical affairs, oncology, AbbVie, talked about: “This FDA submission marks a milestone for CLL remedy with the potential approval for the first oral combination routine of Venclexta and acalabrutinib for beforehand untreated victims with energy blood most cancers. This new fixed-treatment interval technique might allow victims the possibility for day without work remedy, if authorised, and be most likely practice-changing in frontline CLL care.”

Efficacy and safety profile of the model new combination

Detailed data from the AMPLIFY analysis had been shared on the 2024 American Society of Hematology Annual Meeting.

• Outcomes from AMPLIFY demonstrated {{that a}} fixed-duration combination of Venclexta and acalabrutinib diminished the hazard of sickness growth or lack of life by 35% as compared with chemoimmunotherapy (HR 0.65; 95% CI: 0.49–0.87; p=0.004).
• The safety profile of the combo was according to the recognized profiles of each agent when used individually.
• Frequent adversarial events of any grade included neutropenia, bleeding, and COVID-19 an an infection.
• Grade 3 or bigger neutropenia was reported in 26.8% of victims receiving the combo remedy.
• Tumor lysis syndrome occurred generally, with any-grade events seen in merely 0.3% of victims on the Venclexta–acalabrutinib routine versus 3.1% throughout the chemoimmunotherapy group.
• No new safety concerns emerged throughout the AMPLIFY analysis.

Interim AMPLIFY findings

An interim analysis of AMPLIFY was printed in The New England Journal of Remedy (NEJM) earlier in February. The multicenter, open-label trial randomized an entire of 867 victims 1:1:1 all through three arms: 291 had been assigned to acquire acalabrutinib plus venetoclax, 286 acalabrutinib-venetoclax–obinutuzumab, and 290 chemoimmunotherapy.²

“On this interim analysis of the AMPLIFY trial in match victims with beforehand untreated CLL, fixed-duration acalabrutinib–venetoclax (with or with out obinutuzumab) significantly prolonged progression-free survival as in distinction with chemoimmunotherapy,” the analysis authors wrote. “Outcomes for progression-free survival counsel that the benefit of together with obinutuzumab to acalabrutinib–venetoclax was most evident throughout the subgroup with unmutated IGHV (immunoglobulin heavy-chain variable space), which had outcomes that had been very similar to these throughout the subgroup with mutated IGHV.”

CLL14 trial underpinned earlier Venclexta approval

Venclexta’s latest FDA approval throughout the CLL space acquired right here in May 2019 when it was cleared as part of a mixture routine alongside Gazyva (obinutuzumab). This approval was based totally on data from the potential, multicenter, open-label, randomized Part III CLL14 trial (NCT02242942), which confirmed that victims who acquired the routine of Venclexta and Gazyva achieved superior PFS as compared with those who acquired chlorambucil plus obinutuzumab.³

• After a median follow-up of 28 months, remedy with Venclexta plus obinutuzumab diminished the hazard of sickness growth or lack of life by 67% as compared with the combo of chlorambucil and obinutuzumab (HR 0.33; 95% CI: 0.22–0.51; p
• The combination of Venclexta and obinutuzumab moreover led to significantly bigger prices of minimal residual sickness (MRD) negativity, a secondary endpoint indicating deep remission.
• Three months post-treatment, MRD negativity in bone marrow was achieved in 57% of victims receiving Venclexta plus obinutuzumab versus 17% throughout the chlorambucil group (p
• In peripheral blood, MRD negativity was seen in 76% of victims throughout the Venclexta arm, as compared with 35% with chlorambucil plus obinutuzumab (p

References

1. AbbVie Submits for U.S. FDA Approval of Combination Remedy of VENCLEXTA® (venetoclax) and Acalabrutinib for Beforehand Untreated Victims with Continuous Lymphocytic Leukemia (CLL). Data launch. AbbVie. July 29, 2025. Accessed July 29, 2025. https://data.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Combination-Remedy-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Beforehand-Untreated-Victims-with-Continuous-Lymphocytic-Leukemia-CLL

2. Jennifer R. Brown, MD, et al., Fixed-Size Acalabrutinib Mixtures in Untreated Continuous Lymphocytic Leukemia. New England Journal of Remedy. https://www.nejm.org/doi/full/10.1056/NEJMoa2409804. (2025)

3. AbbVie Proclaims US FDA Approval of VENCLEXTA® (venetoclax) as a Chemotherapy-Free Combination Routine for Beforehand Untreated Continuous Lymphocytic Leukemia Victims. Data launch. AbbVie. May 15, 2019. Accessed July 29, 2025. https://data.abbvie.com/2019-05-15-AbbVie-Proclaims-US-FDA-Approval-of-VENCLEXTA-R-venetoclax-as-a-Chemotherapy-Free-Combination-Routine-for-Beforehand-Untreated-Continuous-Lymphocytic-Leukemia-Victims